Prevention of Hepatocellular Carcinoma

 

 Buy Article Permissions and Reprints

ABSTRACT

Prevention is the only realistic approach for reducing mortality rates associated with hepatocellular carcinoma (HCC) worldwide. Vaccination against hepatitis B and screening of blood donations are effective measures of primary prevention. Screening of blood donations has led to a substantial reduction in viral hepatitis transmission among the general population, and in Taiwan vaccination against hepatitis B caused a significant reduction in HCC incidence among infants. Primary prevention also includes approaches that alter epigenetic and genetic changes in hepatocytes, known to increase susceptibility to HCC, as well as treatments slowing progression to cirrhosis. The only evidence that chemoprevention reduces HCC risk is a multicenter randomized prospective study in Asian patients with advanced hepatitis B who received the oral nucleoside analogue lamivudine. Circumstantial evidence suggests that HCC risk is also reduced in patients with chronic hepatitis C who have had a sustained virological response to interferon therapy. HCC is not substantially reduced in patients with hepatitis B treated with interferon and patients with hepatitis C who did not respond to interferon. Secondary prevention, that is, prevention of tumor recurrence after hepatic resection or local ablative therapies, has been pursued with different approaches. Retinoids, hepatic embolization with ¹³¹I lipiodol, and adoptive adjuvant immunotherapy have yielded encouraging results. Other approaches, including those based on interferon alfa or β, provided inconclusive evidence for secondary prophylaxis of HCC, mainly because of the poor methodologies and scientific background of the studies. Dietary interventions and antiaflatoxin agents might help to prevent HCC in susceptible individuals, but the real efficacy of these approaches is far from being demonstrated.

REFERENCES

• 1 Bosch F X, Ribes J, Diaz M, Cléries R. Primary liver cancer: worldwide incidence and trends.  Gastroenterology. 2004;  127 S5-S16
  CrossrefPubMedGoogle Scholar
• 2 Yu M C, Yuan J M. Environmental factors and risk for hepatocellular carcinoma.  Gastroenterology. 2004;  127 S72-S78
  CrossrefPubMedGoogle Scholar
• 3 Bralet M P, Regimbeau J M, Pineau P et al.. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases.  Hepatology. 2000;  32 200-204
  CrossrefPubMedGoogle Scholar
• 4 Schreiber G B, Busch M P, Kleinman S H, Korelitz J J. for the Retrovirus Epidemiology Donor Study . The risk of transfusion-transmitted viral infection.  N Engl J Med. 1996;  334 1685-1690
  CrossrefPubMedGoogle Scholar
• 5 Mele A, Spada E, Sagliocca L et al.. Risk of parenterally transmitted hepatitis following exposure to surgery or other invasive procedures: results from the hepatitis surveillance system in Italy.  J Hepatol. 2001;  35 284-289
  CrossrefPubMedGoogle Scholar
• 6 Chang M H, Chen C J, Lai M S et al.. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group.  N Engl J Med. 1997;  336 1855-1859
  CrossrefPubMedGoogle Scholar
• 7 Jenkins C NH, Buu C, Berger W, Son D T. Liver carcinoma prevention among Asian Pacific Islanders. Getting hepatitis B shots into arms.  Cancer. 2001;  91 252-256
  CrossrefPubMedGoogle Scholar
• 8 Ascherio A, Zhang S M, Hernan M A et al.. Hepatitis B vaccination and the risk of multiple sclerosis.  N Engl J Med. 2001;  344 327-332
  CrossrefPubMedGoogle Scholar
• 9 Goh J, Callagy G, McEntee G et al.. Hepatocellular carcinoma arising in the absence of cirrhosis in genetic haemochromatosis: three case reports and review of the literature.  Eur J Gastroenterol Hepatol. 1999;  11 915-919
  PubMedGoogle Scholar
• 10 Global Alliance for Vaccines and Immunization (GAVI) .Report of the Second Board Meeting, Davos, Switzerland, 31 January 2000; GAVI/00.01, available at www.who.int
• 11 Busch M P. Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients.  Transfus Clin Biol. 2001;  8 200-206
  CrossrefPubMedGoogle Scholar
• 12 Kapusta J, Modelska A, Figlerowicz M et al.. A plant-derived edible vaccine against hepatitis B virus.  FASEB J. 1999;  13 1796-1799
  PubMedGoogle Scholar
• 13 Wogan G N. Aflatoxin as a human carcinogen.  Hepatology. 1999;  30 573-575
  CrossrefPubMedGoogle Scholar
• 14 Wild C P, Hall A J. Primary prevention of hepatocellular carcinoma in developing countries.  Mutat Res. 2000;  462 381-393
  PubMedGoogle Scholar
• 15 Wang J S, Shen X, He X et al.. Protective alterations in phase 1 and 2 metabolism of aflatoxin B₁ by oltipraz in residents of Qidong, People’s Republic of China.  J Natl Cancer Inst. 1999;  91 347-354
  CrossrefPubMedGoogle Scholar
• 16 Egner P A, Wang J B, Zhu Y R et al.. Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer.  Proc Natl Acad Sci USA. 2001;  98 14601-14606
  CrossrefPubMedGoogle Scholar
• 17 Tang L, Tang M, Luo H et al.. Chemoprevention trial of green tea polyphenol in high-risk population of liver cancer: modulation of serum and urinary aflatoxin biomarkers.  Cancer Epidemiol Biomarkers Prev. 2003;  12 1349S , (abst)
  PubMedGoogle Scholar
• 18 La Vecchia C, Negri E, Cavalieri D’Oro L, Franceschi S. Liver cirrhosis and the risk of primary liver cancer.  Eur J Cancer Prev. 1998;  7 315-320
  PubMedGoogle Scholar
• 19 Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors.  Gastroenterology. 2004;  127 S35-S50
  CrossrefPubMedGoogle Scholar
• 20 Morgan M Y. Alcoholic liver disease: natural history, diagnosis, clinical features, evaluation, management, prognosis and prevention. In: Bircher J, Benhamou JP, McIntyre N, et al Oxford Textbook of Clinical Hepatology. 2nd ed. Oxford; Oxford University Press 1999: 1185-1238
  Google Scholar
• 21 Papatheodoridis G V, Manesis E, Hadziyannis S J. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B.  J Hepatol. 2001;  34 306-313
  CrossrefPubMedGoogle Scholar
• 22 Lampertico P, Del Ninno E, Viganò M et al.. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.  Hepatology. 2003;  37 756-763
  CrossrefPubMedGoogle Scholar
• 23 Craxì A, Di Bona D, Cammà C. Interferon-α for HBeAg-positive chronic hepatitis B.  J Hepatol. 2003;  39 S99-S105
  PubMedGoogle Scholar
• 24 Liaw Y F, Sung J JY, Chow W C et al.. Lamivudine for patients with chronic hepatitis B and advanced liver disease.  N Engl J Med. 2004;  351 1521-1531
  CrossrefPubMedGoogle Scholar
• 25 Di Marco V, Marzano A, Lampertico P et al.. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.  Hepatology. 2004;  40 883-891
  CrossrefPubMedGoogle Scholar
• 26 Yoshida H, Shiratori Y, Moriyama M et al.. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance programs of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan.  Ann Intern Med. 1999;  131 174-181
  PubMedGoogle Scholar
• 27 Cammà C, Giunta M, Andreone P, Craxì A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach.  J Hepatol. 2001;  34 593-602
  CrossrefPubMedGoogle Scholar
• 28 Papatheodoridis G V, Papadimitropoulos V, Hadzyiannis S J. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis.  Aliment Pharmacol Ther. 2001;  15 689-698
  CrossrefPubMedGoogle Scholar
• 29 Arase Y, Ikeda K, Marushima N et al.. The long-term efficacy of glycyrrhizin in chronic hepatitis C patients.  Cancer. 1997;  79 1494-1500
  CrossrefPubMedGoogle Scholar
• 30 Habu D, Shiomi S, Tamori A et al.. Role of vitamin K₂ in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver.  JAMA. 2004;  292 358-361
  CrossrefPubMedGoogle Scholar
• 31 Gelatti U, Covolo L, Franceschini M et al.. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study.  J Hepatol. 2005;  42 528-534
  CrossrefPubMedGoogle Scholar
• 32 Kumada T, Nakano S, Takeda I et al.. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma.  Hepatology. 1997;  25 87-92
  PubMedGoogle Scholar
• 33 Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma.  N Engl J Med. 1999;  340 1046-1047
  CrossrefPubMedGoogle Scholar
• 34 Muto Y, Moriwaki H, Ninomiya M et al.. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma.  N Engl J Med. 1996;  334 1561-1567
  CrossrefPubMedGoogle Scholar
• 35 Takayama T, Sekine T, Makuuchi M et al.. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.  Lancet. 2000;  356 802-807
  CrossrefPubMedGoogle Scholar
• 36 Lau W Y, Leunt T WT, Ho S KW et al.. Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial.  Lancet. 1999;  353 797-801
  CrossrefPubMedGoogle Scholar
• 37 Boucher E, Corbinais S, Rolland Y et al.. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma.  Hepatology. 2003;  38 1237-1241
  CrossrefPubMedGoogle Scholar
• 38 Oon C J, Chen W N. Lymphoblastoid alpha-interferon in the prevention of hepatocellular carcinoma (HCC) in high-risk HBsAg-positive resected cirrhotic HCC cases: a 14-year follow-up.  Cancer Invest. 2003;  21 394-399
  CrossrefPubMedGoogle Scholar
• 39 Lin S M, Lin C J, Hsu C W et al.. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors.  Cancer. 2003;  100 376-382
  PubMedGoogle Scholar
• 40 Shiratori Y, Shiina S, Taretani T et al.. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus.  Ann Intern Med. 2003;  138 299-306
  CrossrefPubMedGoogle Scholar
• 41 Ikeda K, Arase Y, Saitoh S et al.. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-a prospective randomized study of hepatitis C virus-related liver cancer.  Hepatology. 2000;  32 228-232
  CrossrefPubMedGoogle Scholar

 Prof.
Massimo Colombo

Department of Gastroenterology and Endocrinology, IRCCS Maggiore Hospital, University of Milan

Via F. Sforza 35, 20122

Milan, Italy

Email: massimo.colombo@unimi.it